This site is intended for health professionals only!

Published on 12 August 2010

Share this story:

FDA “backs transplant patient drug”

teaser

America’s Food and Drug Administration (FDA) has approved a longer length of therapy for a medication treating adult kidney transplant patients at high risk of cytomegalovirus disease, it has been reported.

Valcyte has been developed by Genentech – a member of the Roche Group.

Cytomegalovirus is a common virus that infects most people at some time, rarely causing problems.

But it can cause serious infections for patients who have received organ transplants or in immunodeficient patients – for example those with HIV or AIDS.

Genentech said that longer, preventive treatment with Valcyte reduced the incidence of the disease in high-risk patients from 36.8% to 16.8% a year after they received a transplanted kidney.

Copyright Press Association 2010

Genetech



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: